Pharmacokinetics, Tolerability and Pharmacogenetics of DA-8031 After Multiple Ascending Doses in Healthy Male Subjects
Sejung Hwang,1 Dae Young Lee,2 Joo-Youn Cho,1,3 Jae-Yong Chung,4 In-Jin Jang,1 Kyung-Sang Yu,1,3 SeungHwan Lee1 1Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea; 2Drug Metabolism and Pharmacokinetics (DMPK), D...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2021-06-01
|
Series: | Drug Design, Development and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/pharmacokinetics-tolerability-and-pharmacogenetics-of-da-8031-after-mu-peer-reviewed-fulltext-article-DDDT |
id |
doaj-5dc5f76f3d28484ca93f8f0064ae5adf |
---|---|
record_format |
Article |
spelling |
doaj-5dc5f76f3d28484ca93f8f0064ae5adf2021-06-01T19:51:25ZengDove Medical PressDrug Design, Development and Therapy1177-88812021-06-01Volume 152375238465393Pharmacokinetics, Tolerability and Pharmacogenetics of DA-8031 After Multiple Ascending Doses in Healthy Male SubjectsHwang SLee DYCho JYChung JYJang IJYu KSLee SSejung Hwang,1 Dae Young Lee,2 Joo-Youn Cho,1,3 Jae-Yong Chung,4 In-Jin Jang,1 Kyung-Sang Yu,1,3 SeungHwan Lee1 1Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea; 2Drug Metabolism and Pharmacokinetics (DMPK), Drug Evaluation, Dong-A ST Research Institute, Gyonggi-do, Republic of Korea; 3Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea; 4Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Bundang Hospital, Seongnam, Republic of KoreaCorrespondence: SeungHwan LeeDepartment of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of KoreaTel +82-2-2072-2343Fax +82-2-2072-0720Email leejh413@snu.ac.krPurpose: DA-8031 is a novel selective serotonin reuptake inhibitor for the treatment of premature ejaculation. This study investigated the pharmacokinetics, safety and tolerability of multiple oral doses of DA-8031. In addition, a genetic analysis was explored to evaluate the effect of genetic polymorphisms on the pharmacokinetics of DA-8031.Subjects and Methods: A dose block-randomized, double-blind, placebo-controlled study was conducted in 3 dose groups with 20, 30 and 40 mg of DA-8031. Healthy male subjects were randomized to DA-8031 or placebo at a 4:1 ratio in each dose group of 10 subjects by oral administration once daily for 7 consecutive days. Serial blood and urine samples were collected for the pharmacokinetic evaluation, and the pharmacokinetic-related genes were analyzed by DMETTM plus. A safety evaluation was conducted including adverse events (AEs) monitoring and 12-lead electrocardiogram (ECG).Results: The plasma DA-8031 concentration reached the maximum concentration (Cmax) in 2.2 to 3.0 h and was eliminated with a mean half-life of 25.5 to 26.7 h at steady state. The accumulation index of DA-8031 ranged 2.3 to 2.8. The systemic exposure of DA-8031 of the CYP2D6 intermediate metabolizer (IM) was significantly higher compared to the CYP2D6 poor metabolizer (PM). There were no clinically significant QTc interval changes, and all the adverse events were mild.Conclusion: After multiple oral doses of DA-8031 20, 30, and 40 mg in this study, the systemic exposure of DA-8031 increased in a more than dose-proportional manner with the increasing doses, and DA-8031 was generally well tolerated. In addition, the genetic polymorphisms of CYP2D6 have an impact on the pharmacokinetics of DA-8031.Keywords: selective serotonin reuptake inhibitors, clinical pharmacology, phase 1 study, pharmacogenomicshttps://www.dovepress.com/pharmacokinetics-tolerability-and-pharmacogenetics-of-da-8031-after-mu-peer-reviewed-fulltext-article-DDDTselective serotonin reuptake inhibitorsclinical pharmacologyphase 1 studypharmacogenomics |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Hwang S Lee DY Cho JY Chung JY Jang IJ Yu KS Lee S |
spellingShingle |
Hwang S Lee DY Cho JY Chung JY Jang IJ Yu KS Lee S Pharmacokinetics, Tolerability and Pharmacogenetics of DA-8031 After Multiple Ascending Doses in Healthy Male Subjects Drug Design, Development and Therapy selective serotonin reuptake inhibitors clinical pharmacology phase 1 study pharmacogenomics |
author_facet |
Hwang S Lee DY Cho JY Chung JY Jang IJ Yu KS Lee S |
author_sort |
Hwang S |
title |
Pharmacokinetics, Tolerability and Pharmacogenetics of DA-8031 After Multiple Ascending Doses in Healthy Male Subjects |
title_short |
Pharmacokinetics, Tolerability and Pharmacogenetics of DA-8031 After Multiple Ascending Doses in Healthy Male Subjects |
title_full |
Pharmacokinetics, Tolerability and Pharmacogenetics of DA-8031 After Multiple Ascending Doses in Healthy Male Subjects |
title_fullStr |
Pharmacokinetics, Tolerability and Pharmacogenetics of DA-8031 After Multiple Ascending Doses in Healthy Male Subjects |
title_full_unstemmed |
Pharmacokinetics, Tolerability and Pharmacogenetics of DA-8031 After Multiple Ascending Doses in Healthy Male Subjects |
title_sort |
pharmacokinetics, tolerability and pharmacogenetics of da-8031 after multiple ascending doses in healthy male subjects |
publisher |
Dove Medical Press |
series |
Drug Design, Development and Therapy |
issn |
1177-8881 |
publishDate |
2021-06-01 |
description |
Sejung Hwang,1 Dae Young Lee,2 Joo-Youn Cho,1,3 Jae-Yong Chung,4 In-Jin Jang,1 Kyung-Sang Yu,1,3 SeungHwan Lee1 1Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea; 2Drug Metabolism and Pharmacokinetics (DMPK), Drug Evaluation, Dong-A ST Research Institute, Gyonggi-do, Republic of Korea; 3Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea; 4Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Bundang Hospital, Seongnam, Republic of KoreaCorrespondence: SeungHwan LeeDepartment of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of KoreaTel +82-2-2072-2343Fax +82-2-2072-0720Email leejh413@snu.ac.krPurpose: DA-8031 is a novel selective serotonin reuptake inhibitor for the treatment of premature ejaculation. This study investigated the pharmacokinetics, safety and tolerability of multiple oral doses of DA-8031. In addition, a genetic analysis was explored to evaluate the effect of genetic polymorphisms on the pharmacokinetics of DA-8031.Subjects and Methods: A dose block-randomized, double-blind, placebo-controlled study was conducted in 3 dose groups with 20, 30 and 40 mg of DA-8031. Healthy male subjects were randomized to DA-8031 or placebo at a 4:1 ratio in each dose group of 10 subjects by oral administration once daily for 7 consecutive days. Serial blood and urine samples were collected for the pharmacokinetic evaluation, and the pharmacokinetic-related genes were analyzed by DMETTM plus. A safety evaluation was conducted including adverse events (AEs) monitoring and 12-lead electrocardiogram (ECG).Results: The plasma DA-8031 concentration reached the maximum concentration (Cmax) in 2.2 to 3.0 h and was eliminated with a mean half-life of 25.5 to 26.7 h at steady state. The accumulation index of DA-8031 ranged 2.3 to 2.8. The systemic exposure of DA-8031 of the CYP2D6 intermediate metabolizer (IM) was significantly higher compared to the CYP2D6 poor metabolizer (PM). There were no clinically significant QTc interval changes, and all the adverse events were mild.Conclusion: After multiple oral doses of DA-8031 20, 30, and 40 mg in this study, the systemic exposure of DA-8031 increased in a more than dose-proportional manner with the increasing doses, and DA-8031 was generally well tolerated. In addition, the genetic polymorphisms of CYP2D6 have an impact on the pharmacokinetics of DA-8031.Keywords: selective serotonin reuptake inhibitors, clinical pharmacology, phase 1 study, pharmacogenomics |
topic |
selective serotonin reuptake inhibitors clinical pharmacology phase 1 study pharmacogenomics |
url |
https://www.dovepress.com/pharmacokinetics-tolerability-and-pharmacogenetics-of-da-8031-after-mu-peer-reviewed-fulltext-article-DDDT |
work_keys_str_mv |
AT hwangs pharmacokineticstolerabilityandpharmacogeneticsofda8031aftermultipleascendingdosesinhealthymalesubjects AT leedy pharmacokineticstolerabilityandpharmacogeneticsofda8031aftermultipleascendingdosesinhealthymalesubjects AT chojy pharmacokineticstolerabilityandpharmacogeneticsofda8031aftermultipleascendingdosesinhealthymalesubjects AT chungjy pharmacokineticstolerabilityandpharmacogeneticsofda8031aftermultipleascendingdosesinhealthymalesubjects AT jangij pharmacokineticstolerabilityandpharmacogeneticsofda8031aftermultipleascendingdosesinhealthymalesubjects AT yuks pharmacokineticstolerabilityandpharmacogeneticsofda8031aftermultipleascendingdosesinhealthymalesubjects AT lees pharmacokineticstolerabilityandpharmacogeneticsofda8031aftermultipleascendingdosesinhealthymalesubjects |
_version_ |
1721410117147033600 |